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Aneuploidy is a common feature of human tumors, often correlating with poor prognosis. The mitotic spindle
checkpoint is thought to play a major role in aneuploidy suppression. To investigate the role of the spindle
checkpoint in tumor suppression in vivo, we developed transgenic mice in which thymocytes express a
dominant interfering fragment of Bub1, a kinase regulator of the spindle checkpoint. We report that, despite
high-level expression of dominant-negative Bub1 (Bub1DN), a protein known to inhibit spindle checkpoint
activity in cultured cells, thymocytes show no evidence of spindle checkpoint impairment. Transgenic animals
also failed to show an increased predisposition to spontaneous tumors. Moreover, the Bub1DN transgene failed
to alter the timing or characteristics of thymic lymphoma development in p53 heterozygous or homozygous null
backgrounds, indicating that the lack of tumorigenesis is not due to suppression by p53-dependent check-
points. These results indicate that overexpression of a Bub1 N-terminal fragment is insufficient to impair the
spindle checkpoint in vivo or to drive tumorigenesis in the highly susceptible murine thymocyte system, either
alone or in combination with G1 checkpoint disruption.
Genomic instability and aneuploidy are hallmarks of human
cancer and frequently correlate with poor prognosis (33). De-
spite this common observation, the mechanisms by which an-
euploidy arises and its role in tumorigenesis remain subjects of
intense interest and debate (20). The spindle checkpoint sup-
presses chromosome segregation errors and aneuploidy by en-
suring that all chromosomes achieve proper alignment and
bipolar attachment to the mitotic spindle prior to anaphase
onset (1, 27). The spindle checkpoint controls anaphase entry
by blocking the activity of the anaphase-promoting complex
(APC), a multisubunit ubiquitin ligase that degrades anaphase-
blocking substrates such as Securin proteins (11, 27). Several
genes are required for spindle checkpoint function in the yeast
Saccharomyces cerevisiae, including BUB1, BUB3, MAD1,
MAD2, MAD3, and MPS1, and homologs in metazoans appear
to play conserved roles (reviewed in reference 6).
Several observations suggest that spindle checkpoint dereg-
ulation contributes to tumorigenesis. First, dominant-negative
mutations or decreased expression of spindle checkpoint genes
has been found in some human colon cancers and colon or
other carcinoma cell lines, suggesting a role in the etiology of
chromosome instability in those tumors (8, 34, 36, 41, 42).
Second, several cases of the rare familial disorder mosaic var-
iegated aneuploidy, which presents with developmental abnor-
malities, widespread aneuploidy, and increased risk of tumor-
igenesis, displayed biallelic mutations of the spindle
checkpoint gene BubR1 (18). Third, mice with heterozygous
mutations of the spindle checkpoint gene Mad2, BubR1, Bub3,
or Rae1 are prone to spontaneous or carcinogen-induced tu-
morigenesis (3, 13, 29). Fourth, dominant-negative mutations
in the Bub1 or BubR1 gene have been identified in thymic
lymphomas from mice homozygous for a truncating mutation
in the Brca2 gene (26). Finally, the Tax protein from human
T-cell leukemia virus may drive chromosomal instability in
human adult T-cell leukemia cells by interacting with Mad1
(21). Despite this evidence, mutations in known spindle check-
point genes are rare in a variety of human carcinomas (7, 19,
30, 44), suggesting that genomic instability in such tumors
either results from mutations in presently unknown spindle
checkpoint genes or occurs through alternative mechanisms
such as epigenetic reduction of gene expression. Thus, addi-
tional studies are required to define the contribution of spindle
checkpoint defects in tumorigenesis.
In light of previous studies implicating spindle checkpoint
impairment in thymic lymphomas in Brca2 mutant mice (26),
and given the highly proliferative status of thymocytes and the
high susceptibility of mouse thymocytes to tumorigenesis, we
reasoned that the thymus would provide a good model system
in which to test the role of spindle checkpoint impairment in
tumorigenesis. Overexpression of N-terminal fragments of the
Bub1 kinase impairs the spindle checkpoint in yeast and mam-
malian cell lines, suggesting that a similar approach could be
used for dominant checkpoint inhibition in vivo (16, 26, 38, 43).
Here we report the results of thymocyte overexpression of a
dominant-negative Bub1 in transgenic mice alone and in com-
bination with p53 mutation.
MATERIALS AND METHODS
Transgenic animals. All animal studies were carried out in strict compliance
with federal and local guidelines for animal care and use. The LBDN (Lck–
Bub1–dominant-negative) transgene was produced by cloning the Bub1 cDNA
region encoding amino acids 1 to 331 (Bub1DN) into the BamHI site of the
p1017 vector (10) (a gift from Lishan Su, University of North Carolina, Chapel
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Hill). The Bub1DN fragment was amplified from mouse testis cDNA by PCR. A
primary reaction was performed using primers Bub1NPCR (5-TGGTGGGGT
ATTTCGCCGCT-3) and Bub1CPCR (5-TGGCTGCACTTTGCATGGTG-
3), followed by a second round of amplification using primers Bub1UBam
(5-TGCGCGGGATCCGCCACCATGGACAACCTAGAAAATGTCT-3) and
Bub1LBam (5-AGATCTGGATCCTCACTGGGAGCAAGTATTTTGTCCAA
C-3). The resulting product was digested with BamHI and inserted into the vector.
The Myc-tagged version of the transgene was produced by amplifying the Bub1DN
coding region from the LBDN vector with primers that incorporated the Myc tag in
place of the initiating methionine. A primary amplification was performed with
primers Bub1Myc1 (5-CTCATCTCAGAAGAGGACCTGTCTAGAGACAACC
TAGAAAATGTC-3) and Bub1LBam, followed by a second round of PCR using
Bub1Myc2-2 (5-GCCTGAAGATCTGCCACCATGGAACAAAAACTCATCTC
AGAAGAGGACCT-3) and Bub1LBam. The MycBub1DN product was digested
with BamHI and BglII and cloned into the BamHI site of a modified p1017 vector
in which the native XbaI site was destroyed by Klenow treatment and ligation. A
single clone with the insert in the wrong orientation was subsequently digested with
BstYI and religated to produce a clone with the correct orientation. Transgenes were
removed from vector sequences by digestion with SacII. Transgenic animals were
generated by pronuclear injection in the B6D2F1/J genetic background. Transgenic
animals were identified by PCR of toe-derived DNA using primers LckFPCR1
(5-GGCTGAGGCTGAGGGTTGACTCTAA-3) and BubRPCR2 (5-AAACTG
ATGACGGTCGCTGTTGTACT-3). Cycling parameters were 94°C for 4 min; 35
cycles of 94°C for 30 s, 65°C for 30 s, and 72°C for 30 s; and a final incubation at 72°C
for 10 min.
Antibody production. The Bub1DN fragment was cloned into the pET-His-3E
vector. His-tagged Bub1DN protein was expressed in BL21(DE3) bacteria and
purified on His-Bind resin (Novagen). Purified protein was used to generate a
polyclonal rabbit antiserum (Pocono Rabbit Farm and Laboratory).
Immunoblotting. Tissues were flash frozen in liquid nitrogen and stored at
80°C. Proteins were extracted in radioimmunoprecipitation buffer and quan-
tified by the Bradford method (Bio-Rad). Ten micrograms of protein per sample
was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to a polyvinylidene difluoride membrane. Membranes were probed
with an unpurified Bub1 polyclonal antiserum or the anti-Myc monoclonal an-
tibody 9E10. Immunocomplexes were detected using enhanced chemilumines-
cence (Amersham). Equal loading was verified using an anti–beta-actin antibody
(Santa Cruz Biotechnology; SC-8432). In some cases, extracts were prepared by
solubilizing thymocytes in sodium dodecyl sulfate sample buffer. A lysate from
equivalent cell numbers was loaded in each lane of the gel.
Flow cytometry. Thymus, spleen, and lymph nodes were dissociated by crush-
ing through a 70-m screen and resuspended in FWB (phosphate-buffered saline
with 1% fetal bovine serum and 0.1% [wt/vol] sodium azide). Spleen samples
were treated with erythrocyte lysis solution (8.3 g NH4Cl, 1g KHCO3 per liter of
water), spun down, and resuspended in FWB. Cells were counted in a hemocy-
tometer, and 1  106 cells were stained with saturating amounts of a phyco-
erythrin-conjugated anti-CD4 (CD4) and a fluorescein isothiocyanate-conju-
gated CD8 antibody (BD Bioscience). Samples were analyzed on a FACScan
flow cytometer.
Thymocyte culture. Thymocytes were dissociated as described above and cul-
tured in cDMEM (DMEM-H with 10% fetal bovine serum, 2 mM L-glutamine,
10 mM HEPES, 50 M -mercaptoethanol, 1 penicillin-streptomycin) with 10
ng/ml interleukin-1 (IL-1) (PeproTech) and 20 ng/ml IL-2 (R&D Systems or
PeproTech).
Mitotic checkpoint challenge. Thymocytes were cultured for 5 to 7 days in
cDMEM with interleukin-1 and interleukin-2 and were subsequently treated
for 8 h with 200 ng/ml nocodazole (Sigma). Cells were fixed with 1% formalde-
hyde in phosphate-buffered saline for 20 to 30 min at room temperature, fol-
lowed by 70% ethanol overnight at 20°C. Cells were rehydrated and stained
with an anti-phosphohistone H3 (PH3) antibody and propidium iodide as de-
scribed elsewhere (14), except that we used 1 g anti-PH3 (Upstate), 10 g/ml
Alexa 488-conjugated goat anti-rabbit secondary antibody (Molecular Probes),
FIG. 1. Design and expression of the LBDN transgene in mice. (A) Schematic of the mouse Bub1 gene, the dominant-negative Bub1 fragment,
and the LBDN transgene. lck Pr., lck proximal promoter; hGH, human growth hormone gene; sp/pA, splicing/polyadenylation signals. (B) Anti-
Bub1 immunoblot (I.B.) showing Bub1DN expression in thymuses from four founder lines. Positions of 40- and 50-kDa protein markers are
indicated. (C) Anti-Bub1 immunoblot comparing thymocyte expression levels of Bub1DN (lower arrow) and endogenous Bub1 (120 kDa; upper
arrow). Lane 1, nontransgenic; lane 2, Tg-LBDN-1. Molecular size marker positions are indicated on the left. (D) Anti-Myc tag immunoblot
showing Bub1DN expression in thymus, spleen, and lymph node samples from animals of lines 1 and 2. Both lines show strong expression in the
thymus, with weaker expression in the spleen and lymph node. Results for a nontransgenic control animal are shown on the right. (E) (Top)
Anti-Bub1 immunoblot of thymus (Th), bone marrow (BM), heart (He), kidney (Kd), liver (Lv), lung (Lu), lymph node (LN), skeletal muscle (Mu),
spleen (Sp), and testis (Te) lysates from a Tg-LBDN line 1 transgenic mouse () and a nontransgenic littermate (). A lysate from Bub1DN-
transfected 293 cells was used as a positive control (cont.). (Bottom) Anti-beta-actin immunoblot demonstrating equal protein loading.
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and 100 g/ml propidium iodide. Mitotic indices were measured by flow cytom-
etry on a FACScan by analyzing the percentage of PH3-positive cells with 4N
DNA content as described elsewhere (14). Cell cycle profiles were modeled from
DNA width-versus-DNA area plots with the ModFit LT program (Verity Soft-
ware House).
Survival and tumorigenesis analysis. Animals were monitored regularly for
signs of illness up to the age of 2 years. Overall and tumor-free survival times and
P values were determined by Kaplan-Meier and log rank analyses (Wilcoxon P
values are also shown in some cases for comparison). Animals that were tumor
free at necropsy were censored in survival analyses. Animals that died of un-
known causes were also censored in lymphoma-free survival analysis but not in
overall survival analyses. Lymphoma diagnoses were based on histological con-
firmation of tumors. Comparison of tumor frequencies was done by Fisher’s
exact test with one-tailed P values. All statistical analyses were performed with
JMP IN software (SAS Institute, Inc.).
RESULTS
Thymic overexpression of dominant-negative Bub1. We
used a transgenic approach to express a dominant-negative
fragment of the Bub1 kinase (Bub1DN) specifically in the
mouse thymocytes. Using cell culture systems, others have
reported that expression of an N-terminal Bub1 fragment dom-
inantly impairs the spindle checkpoint (2, 16, 26, 38). This
fragment includes the conserved domain responsible for kinet-
ochore localization and Bub3 binding and is hypothesized to
interfere with checkpoint function via competitive removal of
wild-type Bub1 from the kinetochore. Overexpression of a
similar Bub1 fragment also impairs chromosome segregation
in Saccharomyces cerevisiae (43). The transgene construct con-
sisted of the lck proximal promoter, the Bub1DN cDNA, and
splicing/polyadenylation signals from the human growth hor-
mone gene (Fig. 1A). Two similar constructs were generated,
one of which included an N-terminal Myc epitope tag on the
Bub1DN fragment while the second lacked the Myc tag. Seven
transgenic mouse lines (four with the Myc tag, three without)
were derived on a B6D2F1/J genetic background via pro-
nuclear injection. Strong expression of the Bub1DN protein
was detected in thymus extracts from four founder lines by
immunoblotting (lines 1 and 2 with the Myc tag, lines 3 and 4
without) (Fig. 1B and data not shown). Importantly, the
Bub1DN protein was expressed in the thymus at much higher
levels than the 120-kDa protein presumed to be endogenous
Bub1, which was difficult to detect under standard conditions
(Fig. 1C). Weak Bub1DN expression was also sometimes de-
tected in spleen and lymph node extracts, consistent with pre-
vious reports of transgenes driven by the lck proximal pro-
moter (Fig. 1D and E) (5, 35). To determine the specificity of
transgene expression, several tissues from an animal of
founder line 1 and a nontransgenic littermate were similarly
examined (Fig. 1E). Bub1DN expression was detected only in
the thymus and testes, while nonspecific bands were detected
in the heart, liver, and muscle. Based on these results, founder
lines 1 and 2 were chosen for further analyses. These animals
are referred to here as transgenic LBDN (Tg-LBDN) animals.
Bub1DN effects on thymocyte development. We analyzed
transgenic animals to determine if Bub1DN expression induces
overt thymic or T-cell phenotypes. Thymocyte counts from
young animals showed no difference between transgenic ani-
mals and controls. However, 3- to 6-month-old transgenic an-
imals displayed a modest reduction in total thymocytes (Fig.
2A). Flow cytometry analyses demonstrated that thymocyte
subsets were not significantly different between transgenic and
nontransgenic littermates at the ages of 2.5 (Fig. 2B) and 6.5
(data not shown) months. Similarly, no significant differences
were observed in B- and T-cell percentages found in spleen
and lymph node samples (Fig. 2B). These data indicate that
overexpression of the Bub1DN fragment does not cause overt
disruption of T-cell development but does cause modest re-
ductions in thymocyte numbers as animals age.
While the Bub1DN transgenic animals did not display dra-
matic T-cell phenotypes, it remained possible that spindle
checkpoint impairment occurred in these animals. If so, trans-
genic thymocytes should display reduced mitotic accumulation
upon treatment with the spindle inhibitor nocodazole. To test
FIG. 2. The LBDN transgene causes reduced thymocyte numbers in aged animals but does not alter thymocyte and peripheral T-cell
populations. (A) Mean thymocyte numbers from young (	3 months; n 
 4 per genotype) and older (3 to 6.5 months; n 
 13 Tg-LBDN, 10
Tg-LBDN) animals of LBDN line 1 and controls. Error bars, standard errors of the means. (B) Representative flow cytometry analyses of CD4
and CD8 expression in thymus, spleen, and lymph node samples from 2.5-month-old Tg-LBDN-positive and -negative animals. Percentages of cells
are indicated in each quadrant.
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this hypothesis, thymocytes were cultured in vitro with IL-1
and IL-2, and mitotic indices were compared for mock-treated
versus nocodazole-treated (8-h) samples. Importantly, IL-1
and IL-2 promoted robust proliferation while retaining
Bub1DN expression (Fig. 3A). In two separate experiments,
mitotic indices increased 5- to 10-fold in nocodazole-treated
samples. Surprisingly, thymocytes from LBDN animals did
not show any reduction in mitotic arrest relative to that in
nontransgenic controls (Fig. 3B). These data indicate that the
spindle checkpoint is intact in LBDN thymocytes, despite the
observation that Bub1DN protein is highly expressed.
In performing the nocodazole challenge experiments, we
noted that thymocytes from 6.5-month-old LBDN animals
proliferated poorly relative to those from their nontransgenic
counterparts (data not shown). Similar defects were not ob-
served in thymocytes from young animals, suggesting a possible
link to the reduced thymocyte numbers observed in these older
mice. The basis of this proliferation defect is presently unclear,
and it remains possible that the reduced proliferation is a
result of chromosome segregation errors or other mitotic de-
fects that are more pronounced as animals age. We attempted
to address this question by analyzing aneuploidy rates of trans-
genic and nontransgenic thymocytes after 5 to 10 days of un-
perturbed culture. No gross differences were observed, al-
though aneuploidy rates of both nontransgenic and transgenic
cells differed widely among experiments, likely reflecting lim-
itations associated with in vitro thymocyte culture (data not
shown). Hence, while the results described above clearly indi-
cate that the Bub1DN fragment fails to impair the spindle
checkpoint response to nocodazole, it is possible that mitotic
dynamics are impaired in ways not detectable by standard in
vitro assays.
Bub1DN expression does not alter survival or tumorigene-
sis. Aberrant chromosome segregation and aneuploidy have
been proposed to contribute to tumorigenesis (20). According
to this hypothesis, if the Bub1DN transgene increases chromo-
some segregation errors and aneuploidy in even a subset of
thymocytes in vivo, such events would be expected to increase
the risk of tumorigenesis. To test this proposal, survival anal-
ysis was performed using cohorts of Bub1DN transgenic ani-
mals from founder lines 1 and 2 and controls. Animals were
sacrificed when obviously ill or when they reached the age of 22
to 24 months. Animals sacrificed at the study end point were
censored in survival data if they did not display overt abnor-
malities or tumors. Overall survival of transgenic animals and
controls was equivalent (Fig. 4A), and animals from all cohorts
displayed similar incidences of age-related abnormalities such
as adenomas and carcinomas of the liver and lung (data not
shown). Because the LBDN transgene is expressed only in
lymphocytes, the most likely tumor expected from transgene
activity would be thymic or disseminated lymphoma. We noted
one thymic lymphoma and one possible disseminated lym-
phoma in transgenic animals of Tg-LBDN line 1 (Tg-LBDN-1)
(2/53; 4%), one possible disseminated lymphoma in an animal
from line 2 (1/19; 5%), and no lymphomas among 22 control
animals. However, these tumor frequency differences are not
statistically significant (P 
 0.44 for combined Tg-LBDN
versus nontransgenic animals), and censoring survival data by
the presence or absence of lymphomas also failed to show a
FIG. 3. LBDN thymocytes have a normal spindle checkpoint re-
sponse. (A) Anti-Bub1 immunoblot (I.B.) demonstrating Bub1DN ex-
pression in cultured thymocytes. Thymocytes from a Tg-LBDN (odd-
numbered lanes) or a nontransgenic (even-numbered lanes) mouse
were cultured in IL-1 plus IL-2 for 0 (lanes 1 and 2), 3 (lanes 3 and
4), or 5 (lanes 5 and 6) days. Lysates were probed with an anti-Bub1
antibody. (B) Spindle checkpoint responses of cultured thymocytes.
Mitotic indices were determined for mock-treated or nocodazole-
treated (8 h) thymocytes of the genotypes indicated. Fold increase
(Inc.) represents treated/untreated mitotic index. Data are means 
standard errors of the means for two experiments. Two animals were
used per genotype per experiment. The apparent difference in exper-
iment 1 was not statistically significant (P 
 0.11).
FIG. 4. The LBDN transgene has no effect on survival. (A) Kaplan-
Meier analysis of overall survival in mice from Tg-LBDN line 1 (n 

54), Tg-LBDN line 2 (n 
 19), and nontransgenic littermate controls
(n 
 22). (B) Kaplan-Meier analysis of overall survival among p53-
heterozygous or homozygous null mice with or without the LBDN (line
1) transgene (Tg-LBDN-1 p53/ [n 
 32], Tg-LBDN-1 p53/ [n 

20], Tg-LBDN-1 p53/ [n 
 17], and Tg-LBDN-1 p53/ [n 
 11]).
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statistically significant survival difference (data not shown).
Together, these data suggest that thymic overexpression of the
Bub1DN fragment has no significant effect on survival or tu-
morigenesis.
p53 checkpoint inactivation does not reveal a Bub1DN ef-
fect. Because the cellular consequences of spindle checkpoint
impairment and chromosome missegregation are not well de-
fined, we considered the possibility that p53-dependent cell
cycle checkpoints might override tumorigenic effects of
Bub1DN expression. That is, cells with chromosomal aberra-
tions may be removed from the system by p53-dependent ar-
rest or apoptosis. If so, the introduction of p53 mutations in
Tg-LBDN transgenic animals would be expected to cooperate
with Bub1DN expression in tumorigenesis. Additionally, if
Bub1DN expression increases the rate of chromosome misseg-
regation in vivo, Tg-LBDN mice on a p53 heterozygous back-
ground should be more likely to experience loss of the wild-
type p53 allele in thymocytes or T cells. Loss of the wild-type
p53 allele has been proposed to be a rate-limiting step in
irradiation-induced tumorigenesis of p53 heterozygous mice
(22). To test these hypotheses, survival analysis was performed
on cohorts of Tg-LBDN-1 transgenic animals and nontrans-
genic controls generated on p53 heterozygous and homozygous
null backgrounds. Contrary to the hypothesis, mice harboring
the LBDN transgene on a p53 heterozygous background did
not display any overall survival difference from Tg-LBDN-
negative animals (Fig. 4B) (P 
 0.89). Censoring survival data
based on the presence or absence of lymphomas revealed a
trend toward shorter lymphoma-free survival in Tg-LBDN;
p53/ animals, but this trend also failed to reach statistical
significance (P 
 0.18 by the log rank test; P 
 0.06 by the
Wilcoxon test) (survival curve not shown). While a higher
proportion of Tg-LBDN; p53/ animals than of Tg-LBDN;
p53/ animals developed lymphoma (25% versus 10%, re-
spectively), this difference also failed to reach statistical signif-
icance (P 
 0.17). Similarly, the presence or absence of the
LBDN transgene had no significant effect on survival or tumor
spectrum in p53-null animals. Approximately 82% of Tg-
LBDN; p53/ and 73% of Tg-LBDN; p53/ animals de-
veloped thymic lymphomas, and tumor latencies were very
similar (Fig. 3B) (P 
 0.56). Together, these data do not
support a role for p53-dependent suppression of tumorigenesis
in Tg-LBDN mice, nor do they support the hypothesis that the
Bub1DN fragment contributes to thymic tumorigenesis in vivo.
DISCUSSION
Since the discovery of Bub1 mutations in colorectal tumor
cell lines several years ago (8), considerable interest has fo-
cused on the role of spindle checkpoint impairment in human
cancer. Several subsequent studies found that mutations in
known spindle checkpoint genes are rare in a variety of tumors
or tumor cell lines, although checkpoint impairment by epige-
netic mechanisms was observed in some cases (7, 19, 25, 30, 32,
34, 36, 41, 42, 44). These studies cumulatively call into question
the role of spindle checkpoint impairment in cancer.
We examined the consequences of overexpressing a domi-
nant-negative Bub1 fragment in mouse thymocytes in vivo to
determine if spindle checkpoint impairment contributes to
lymphomagenesis. Surprisingly, we did not detect any evidence
that the BubDN protein impaired the spindle checkpoint, as
transgenic thymocytes cultured in vitro arrested normally in
response to nocodazole treatment. The only phenotypes ob-
served in Tg-LBDN mice were (i) a modest reduction in thy-
mocyte numbers with increased age and (ii) impaired in vitro
proliferation of thymocytes from aged animals. Tg-LBDN
mice did not show significantly increased tumor susceptibility.
Heterozygous or homozygous mutation of the p53 gene also
failed to uncover significant tumorigenic effects of the trans-
gene that might have been suppressed by p53-dependent
checkpoints. Together, our data indicate that thymic overex-
pression of Bub1DN has no significant effect on thymic devel-
opment or tumorigenesis.
The Bub1DN fragment used in the present work has been
used extensively in cultured cells, inducing significant spindle
checkpoint impairment (2, 16, 26, 38). For example, HeLa cells
expressing Bub1DN displayed accelerated mitotic passage un-
der normal growth conditions and decreased mitotic arrest and
apoptosis after nocodazole treatment (38). Bub1DN expres-
sion reversed growth arrest and transformed Brca2-deficient
mouse embryonic fibroblasts, rendering them resistant to no-
codazole-induced mitotic arrest (26). There are several possi-
ble explanations for why expression of Bub1DN did not elicit
the same spindle checkpoint effects in thymocytes. First, it is
possible that cell lines used in previous in vitro studies have
accumulated changes in additional factors, “relaxing” the mi-
totic checkpoints and making them abnormally sensitive to
Bub1 inhibition. Thus, the dominant-negative Bub1 fragment
may not be sufficient for checkpoint deregulation in primary
cells. However, the same Bub1DN protein was recently shown
to cause accelerated passage through meiosis I and to disrupt
nocodazole-induced arrest in meiosis II when expressed in
mouse oocytes (39). These results suggest that Bub1DN can
have similar effects in primary cells cultured in vitro, although
effects on meiosis and mitosis could be distinct. Thymocytes
could also be resistant to the dominant-negative effects via
differences in spindle checkpoint regulation or in expression
levels of spindle checkpoint components. The lack of effect
could also be due to technical challenges associated with the
animal studies described here. For example, it is possible that
Bub1DN expression levels achieved in Tg-LBDN mice are
insufficient to completely override endogenous Bub1 function
in thymocytes. However, we have shown that the Bub1DN
fragment is expressed at significantly higher levels than endog-
enous Bub1. It has been noted that this fragment displays
dominant-negative activity in cell culture only when the cells
are challenged with spindle inhibitors (2). Nevertheless, that
observation differs from other reports in which the same frag-
ment caused shortened mitosis in untreated HeLa cells (16,
38). Such differences could reflect distinct spindle checkpoint
regulation in distinct cell types, different levels of Bub1DN
expression, or other unknown, variables between studies. It is
noteworthy that an amino-terminal fragment of yeast Bub1
supports partial spindle checkpoint activity in vivo, indepen-
dently of the C-terminal kinase domain. Nevertheless, overex-
pression of full-length wild-type or N-terminal Bub1 fragments
in yeast caused chromosome segregation errors, supporting a
dominant-negative effect due to overexpression (43). Thus,
while the evidence supporting dominant-negative activities of
Bub1 N-terminal fragments is compelling in yeast and cell
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culture systems, the behavior of these fragments in distinct cell
types in vivo will need to be carefully evaluated to determine if
dominant activities are induced.
The equivalent survival of p53 heterozygous mice with or
without the LBDN transgene supports the conclusion that the
Bub1DN fragment does not induce significant genomic insta-
bility in vivo. p53 heterozygous mice have a shortened life span
and high rates of thymic lymphomagenesis in response to ir-
radiation or chemical mutagenesis, both of which elicit in-
creased genomic instability (22). The majority of irradiation-
induced tumors in p53 heterozygous mice display loss of the
wild-type p53 allele (p53LOH), suggesting that p53 loss plays a
key role in tumor development. If thymic expression of the
Bub1DN protein in Tg-LBDN mice induced significant
genomic instability, the frequency of p53LOH and subsequent
tumorigenesis should be greater in Tg-LBDN p53/ animals
than in controls. The absence of such cooperativity in our
experimental cohorts supports the conclusion that the
Bub1DN protein does not elicit significant genomic instability
in vivo.
A potential caveat in interpreting tumorigenesis data in this
study concerns the use of the lck proximal promoter for thymic
expression of Bub1DN. It is possible that Tg-LBDN mice do
not develop tumors because the transgene is not expressed in
cell types relevant to the transformation process. The originat-
ing cell type of most cancers is controversial, but significant
evidence suggests a stem cell origin for many cancers (31). It is
thus possible that spindle checkpoint impairment and/or chro-
mosome missegregation in hematopoietic stem or progenitor
cells would initiate tumorigenesis, while similar effects in
more-differentiated thymocytes would not. Even within the
thymus, lesions may need to occur in specific thymocyte sub-
sets, most likely the proliferative subsets, to drive tumorigen-
esis. Thymocytes pass through several developmental stages
marked by expression of specific cell surface markers and by
regulated proliferation (15, 17). Early thymocyte subsets that
lack CD4 and CD8 expression (double-negative [DN] cells)
represent only 1 to 2 percent of total thymocytes but account
for a significant portion of thymocyte proliferation. DN thy-
mocytes are divided into four subtypes (DN1 to DN4) based on
expression of the CD44, CD25, and CD117 surface markers.
The DN3 (CD44 CD25 CD117) and DN4 (CD44 CD25
CD117) subsets make up approximately 90% of DN thymo-
cytes and display high proliferative activity that gives rise to the
large numbers of CD4 CD8 (double-positive [DP]) thymo-
cytes (15). Thus, LBDN transgene expression in the prolifer-
ative DN3 and DN4 thymocyte subsets would provide the
greatest opportunity for chromosome missegregation events
that may facilitate tumor formation. Our data suggest that the
LBDN transgene is expressed in DN thymocytes, since
Bub1DN expression was maintained in cells cultured in IL-1
and IL-2. These conditions produced a predominant DN pop-
ulation after 1 week of culture (data not shown), consistent
with published reports that IL-1 and IL-2 stimulate DN thy-
mocyte proliferation (37). Our results are also consistent with
a study of four transgenic mouse lines in which the same lck
promoter and RNA processing signals used here drive green
fluorescent protein (GFP) expression. All four lines of lck-
GFP transgenic mice initiated GFP expression by the DN3
stage, with some lines expressing GFP as early as the DN1
stage (5). This expression pattern is also consistent with the
mRNA expression of the endogenous lck gene, which is de-
tectable in all DN subsets (5). We also note that several trans-
genes driven by the lck proximal promoter do elicit tumors in
transgenic animals, indicating that the cells targeted by this
promoter can be transformed in vivo (9, 12, 23, 28, 40). Thus,
while we cannot rule out the possibility that Bub1DN would
need to be expressed in stem cells to elicit tumorigenesis, the
simplest explanation for our data is that the Bub1DN protein
does not display sufficient dominant-negative activity to impair
the spindle checkpoint in thymocytes.
The decreases in proliferation and overall thymocyte num-
bers in aged LBDN animals are puzzling given the lack of any
apparent spindle checkpoint phenotype. Flow cytometry pro-
files of stimulated cells showed lower percentages of blasts as
evidenced by forward and side scatter properties, suggesting
that transgenic cells may be defective in responding to stimu-
lation and/or cell cycle entry (data not shown). It is unclear
how the LBDN transgene might cause such a defect and why it
would be observed only in older mice. Additional analyses will
be needed to understand the basis of this modest phenotype.
Nevertheless, our data strongly indicate that the LBDN trans-
genic mice are not a suitable model for spindle checkpoint
disruption in thymocytes.
Thus, additional mouse models will be required in order to
definitively address the roles of bub1 mutation, spindle check-
point impairment, and chromosome instability in tumorigene-
sis. The caveats involved in interpreting dominant-negative
data such as those described here suggest the need for care in
developing such models. While mice heterozygous for Mad2,
BubR1, Rae1, and Bub3 display some increased propensity for
tumorigenesis (3, 13, 29), it remains unclear whether the ob-
served tissue specificity reflects distinct spindle checkpoint reg-
ulation or special sensitivity in those tissues. A conditional
knockout strategy represents the best initial strategy to define
the role for the spindle checkpoint in specific cell types in vivo.
The availability of transgenic mice expressing the cre recombi-
nase from a variety of promoters will allow tests in specific cell
types in vivo. However, because the spindle checkpoint may
play an essential role in normal cell division, it is possible that
complete ablation will also be incompatible with tumorigene-
sis. In line with this hypothesis, a recently described hypomor-
phic mutation in the BubR1 gene caused aneuploidy and pre-
mature aging phenotypes without increasing tumorigenesis (4),
and reduction of Mad2 and BubR1 expression by RNA inter-
ference in human cancer cell lines was lethal (24). It is note-
worthy that spindle checkpoint mutations identified in human
tumors to date are all heterozygous mutations suggested to
confer dominant-negative activities (8, 26, 32). Such dominant
mutations may confer sufficient checkpoint impairment for
tumorigenesis while allowing enough residual activity for cell
survival. Thus, conditional knock-in models of tumor-derived
spindle checkpoint mutants may ultimately prove to be the best
way to fully investigate the role of spindle checkpoint impair-
ment in tumorigenesis in various tissues in vivo.
In conclusion, our results indicate that thymic overexpres-
sion of an amino-terminal Bub1 fragment does not disrupt the
spindle checkpoint or promote tumorigenesis in mouse thymo-
cytes, despite evidence from yeast and cell culture systems that
the Bub1 fragment used in this study induces checkpoint im-
VOL. 25, 2005 DOMINANT-NEGATIVE Bub1 FAILS TO INDUCE TUMORIGENESIS 7801
pairment. This suggests that distinct cell cycle control mecha-
nisms or redundancy may limit the effects of some dominant
inhibitors in vivo, suggesting the need for caution in the use of
such reagents. Our data also suggest that chromosome misseg-
regation phenotypes observed in cell culture, such as those
elicited by this reagent, may not accurately predict in vivo
relevance.
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